Share

June 2016; 3 (3) ArticleOpen Access

Natalizumab-induced POU2AF1/Spi-B upregulation

A possible route for PML development

Maria Meira, Claudia Sievers, Francine Hoffmann, Aiden Haghikia, Maria Rasenack, Bernhard F. Décard, Jens Kuhle, Tobias Derfuss, Ludwig Kappos, Raija L.P. Lindberg
First published March 31, 2016, DOI: https://doi.org/10.1212/NXI.0000000000000223
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1855

Share

Article Information

vol. 3 no. 3 e223
DOI: 
https://doi.org/10.1212/NXI.0000000000000223
PubMed: 
27088119
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received November 5, 2015
  • Accepted in final form February 10, 2016
  • First Published March 31, 2016.
Copyright & Usage: 
© 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Maria Meira, PhD,
    2. Claudia Sievers, PhD,
    3. Francine Hoffmann, BSc,
    4. Aiden Haghikia, MD,
    5. Maria Rasenack, MD,
    6. Bernhard F. Décard, MD,
    7. Jens Kuhle, MD,
    8. Tobias Derfuss, MD,
    9. Ludwig Kappos, MD and
    10. Raija L.P. Lindberg, PhD
  1. Maria Meira, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Claudia Sievers, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Francine Hoffmann, BSc,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Aiden Haghikia, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Maria Rasenack, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Bernhard F. Décard, MD,
    7. Scientific Advisory Boards:

    1. Bernhard D?card received for the institution (University Hospital Basel) fees from advisory boards or speaker fees from Biogen, Teva and Novartis, that were used exclusively for research support.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Bernhard D?card received for the institution (University Hospital Basel) fees from advisory boards or speaker fees from Biogen, Teva and Novartis, that were used exclusively for research support. Dr. Bernhard D?card received travel support from Biogen.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Bernhard D?card received for the institution (University Hospital Basel) fees from advisory boards or speaker fees from Biogen, Teva and Novartis, that were used exclusively for research support.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Jens Kuhle, MD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. JK?s institution (University Hospital Basel) received in the last 3 years and used exclusively for research support: Speaker honoraria: (1) Swiss MS Society (2) Biogen (3) Novartis (4) Roche (5) Genzyme Travel expenses: (1) Merck Serono (2) Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Bayer (Schweiz) AG (2) Genzyme (3) Novartis

    Research Support, Government Entities:

    1. (1) Swiss National Research Foundation

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) ECTRIMS Research Fellowship Programme (2) University of Basel (3) Swiss MS Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Tobias Derfuss, MD,
    9. Scientific Advisory Boards:

    1. Scientific advisory boards for (1) Biogen Idec (2) Novartis Pharma (3) Genzyme (4) Merck Serono (5) Bayer Schering (6) Octapharma (7) GeNeuro (8) Roche

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. travel and speaker honoraria from (1) Bayer Schering (2) Biogen Idec (3) Merck Serono (4) Novartis Pharma (5) Genzyme

    Editorial Boards:

    1. Member of the Editorial board of Plos One

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. My wife is an employee of Novartis Pharma.

    Consultancies:

    1. Member of steering committee in Phase II studies by Mitsubishi Pharma and by GeNeuro

    Speakers' Bureaus:

    1. )(1) Biogen Idec (2)Novartis Pharma (3) Merck Serono

    Other Activities:

    1. Member of the Executive board of ECTRIMS (non-profit entity; member of the editorial board of Plos One

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis Pharma (2) Merck Serono (3) Biogen Idec

    Research Support, Government Entities:

    1. (1)PI of a projected funded by the Swiss National Foundation

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Swiss MS Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Ludwig Kappos, MD and
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1)Multiple Sclerosis Journal, (2)Multiple Sclerosis and Related Disorders (3)Journal of Neurology member of the Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1)Actelion, (2)Alkermes, (3)Almirall, (4)Bayer,(5)Biogen Idec, (6)Excemed,(7)GeNeuro SA, (8)Genzyme, (9)Merck, (10)Mitsubishi, (11)Novartis, (12)Receptos, (13)Pfizer, (14)Roche, (15)Sanofi-Aventis, (16)Santhera, (17)Teva, (18)UCB all payments have been transferred to the Research Account of the University Hospital

    Research Support, Government Entities:

    1. Research support by the Swiss National Research Foundation and the European Union

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. The Swiss MS Society and Novartis and Roche Research Foundations.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Raija L.P. Lindberg, PhD
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Swiss Multiple Sclerosis Society, 2012, 2013, 2014, 2015 (2) Swiss National Science Foundation, 2011-2013, 2015-2017 (3) Roche Postdoctoral Fellowship Program, 2010-2013

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From Clinical Neuroimmunology (M.M., C.S., F.H., M.R., B.F.D., J.K., T.D., L.K., R.L.P.L.), Departments of Biomedicine and Neurology, University Hospital Basel, Switzerland; and Department of Neurology (A.H.), St. Josef-Hospital, Ruhr-University Bochum, Germany.
  1. Correspondence to Prof. Lindberg: Raija.lindberg{at}unibas.ch

Article usage

Article usage: March 2016 to October 2023

AbstractFullPdfSource
Mar 20161002Highwire
Apr 201643921551Highwire
Apr 201604323pmc
May 20162822732Highwire
May 201607540pmc
Jun 201635734073Highwire
Jun 201603820pmc
Jul 2016912221Highwire
Jul 201602520pmc
Aug 2016522912Highwire
Aug 20160238pmc
Sep 20164885Highwire
Sep 20160147pmc
Oct 20164357Highwire
Oct 201602215pmc
Nov 20162879Highwire
Nov 20160206pmc
Dec 20161947Highwire
Dec 2016051pmc
Jan 20173875Highwire
Jan 201701615pmc
Feb 20172234Highwire
Feb 20170126pmc
Mar 20172244Highwire
Mar 20170106pmc
Apr 20172365Highwire
Apr 2017467pmc
May 20171674Highwire
May 201731517pmc
Jun 2017804Highwire
Jun 201761013pmc
Jul 20171304Highwire
Jul 2017155pmc
Aug 20171063Highwire
Aug 2017189pmc
Sep 2017701Highwire
Sep 2017555pmc
Oct 2017940Highwire
Oct 2017588pmc
Nov 20172743Highwire
Nov 20174479516pmc
Dec 20172234Highwire
Jan 201851711Highwire
Feb 20180141Highwire
Mar 20180214Highwire
Apr 20181285Highwire
Apr 20184910pmc
May 20185399Highwire
Jun 20180432Highwire
Jun 2018675pmc
Jul 20183404Highwire
Aug 20181454Highwire
Aug 2018378pmc
Sep 20182397Highwire
Oct 20187717Highwire
Nov 20185492Highwire
Dec 20186267Highwire
Jan 201910404Highwire
Feb 20197438Highwire
Mar 201993111Highwire
Apr 20196289Highwire
May 2019155110Highwire
Jun 2019175117Highwire
Jul 201918358Highwire
Aug 2019133012Highwire
Sep 2019154115Highwire
Oct 2019203216Highwire
Nov 2019193415Highwire
Dec 2019265034Highwire
Jan 2020254018Highwire
Feb 2020312813Highwire
Mar 2020102712Highwire
Apr 20200177Highwire
May 202001822Highwire
Jun 2020076Highwire
Jul 20201146Highwire
Aug 20200611Highwire
Sep 202042110Highwire
Oct 202014111Highwire
Nov 202041416Highwire
Dec 202021412Highwire
Jan 202162429Highwire
Feb 202111918Highwire
Mar 202122013Highwire
Apr 202122715Highwire
May 202162016Highwire
Jun 20212145Highwire
Jul 202111922Highwire
Aug 202132913Highwire
Sep 20210189Highwire
Oct 202161732Highwire
Nov 202153127Highwire
Dec 202122612Highwire
Jan 202201812Highwire
Feb 202232010Highwire
Mar 202252611Highwire
Apr 20220169Highwire
May 2022112619Highwire
Jun 202271911Highwire
Jul 202219410Highwire
Aug 202263314Highwire
Sep 202263513Highwire
Oct 202283019Highwire
Nov 202295723Highwire
Dec 2022221513Highwire
Jan 20235389Highwire
Feb 20236299Highwire
Mar 20234178Highwire
Apr 202331812Highwire
May 202331714Highwire
Jun 20232105Highwire
Jul 202311111Highwire
Aug 20231106Highwire
Sep 20235114Highwire
Oct 20232216Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me

Recommended articles